ASCO 2019: T-VEC shows improved survival over cytokine therapy in patients with melanoma

Source: ECancer News, July 2019

Igor Puzanov, MD, Director of the Early Phase Clinical Trials Program and Chief of Melanoma at Roswell Park Comprehensive Cancer Center, led research on the immunotherapy T-VEC, or talimogene laherparepvec, to be presented at the annual meeting of the American Society of Clinical Oncology (ASCO) in Chicago.

Dr. Puzanov is senior author on the study, which is the first to report the ad hoc analysis of progression-free survival (PFS) for T-VEC compared to cytokine-based immunotherapy with granulocyte-macrophage colony-stimulating factor, or GM-CSF, in the pivotal OPTiM randomised phase III trial (NCT identifier no. 00769704).

T-VEC is an injectable immunotherapy designed to kill melanoma cells in the skin and lymph nodes.

read the original full article